A modern genetics laboratory at sunset, featuring DNA analysis on a laptop, a microscope, sample tubes, biotechnology equipment, and a city skyline overlooking the water.

Anne Wojcicki Biography: A Life in Consumer Genetics

by

On March 23, 2025, the company Anne Wojcicki had helped create filed for Chapter 11 bankruptcy protection. She resigned as its chief executive that day, ending a tenure formally documented as beginning in 2010. Yet she would soon lead a bid for the genetics business she helped build.

Four months later, a nonprofit she founded acquired the company’s consumer genetic-testing and research operations for $305 million. The core business passed into a new legal structure, carrying forward both Wojcicki’s long-standing interest in accessible genetic information and the questions surrounding the stewardship of customers’ data.

Long before 23andMe sold its first test kit, Wojcicki was studying biotechnology companies as a healthcare investment analyst.

A Quick Look at the Life of Anne Wojcicki

Biography Summary

Anne E. Wojcicki is an American biotechnology entrepreneur who co-founded 23andMe with Linda Avey and Paul Cusenza in 2006. The company popularized consumer genetic testing and assembled a large opt-in research cohort, but faced FDA intervention, financial difficulties, a major data-security incident and bankruptcy. As of October 23, 2026, Wojcicki leads 23andMe Research Institute, the separate nonprofit that acquired the former company’s core genetics and research operations.

Profile

Full Name: Anne E. Wojcicki

Born: 1973

Nationality: American

Education: Bachelor’s degree in biology, Yale University, 1996

Best Known For: Co-founding 23andMe and advancing direct-to-consumer genetic testing

Original 23andMe Role: Co-founder (2006); chief executive officer (2010–March 23, 2025)

Role as of October 23, 2026: Founder and CEO, 23andMe Research Institute

Science Philanthropy: Founding sponsor of the Breakthrough Prize in Life Sciences

A Stanford Upbringing and a Biology Degree

Born in 1973, Anne was the youngest of three daughters of Stanford physicist Stanley Wojcicki and teacher Esther Wojcicki. Her sisters were Susan, who later led YouTube, and Janet, who pursued academic work in pediatrics and public health. The family lived within the Stanford and Palo Alto university community; Esther taught journalism at Palo Alto High School.

In testimony to Congress decades later, Wojcicki recalled being raised to value civic contribution. She said her mother’s advocacy of patient self-determination helped shape her thinking about health.

She graduated from Yale University in 1996 with a bachelor’s degree in biology. In a later interview, she recalled working with molecular biologist Sidney Altman at Yale, spending summers at the National Cancer Institute and undertaking work at the Weizmann Institute. After graduation, she took her scientific background into biotechnology investment analysis.

Seeing Biotechnology from Wall Street

Wojcicki moved into investment research, analyzing healthcare and biotechnology businesses. Her documented positions included Investor AB from 1996 to 1999, Ardsley Partners from 1999 to 2000, Andor Capital Management from 2001 to 2002 and Passport Capital from 2004 to 2006.

In a 2015 interview, she pushed back on a familiar description of her career: “I was a research analyst on Wall Street. People always call me an investment banker. I was not an investment banker.”

Looking back, Wojcicki said she was dissatisfied by what she perceived as insufficient attention to prevention and patients’ experiences in parts of the healthcare industry. She considered medical school, took the MCAT and volunteered in a San Francisco emergency department, according to her own recollection, but said she never applied.

Wojcicki later traced the idea for 23andMe to the convergence of more affordable genetic testing, the consumer internet and the possibility of large voluntary research cohorts. She recalled meeting Linda Avey around late 2005 and developing related ideas with her. In 2006, Wojcicki, Avey and Paul Cusenza co-founded 23andMe.

Turning a Saliva Sample into a Consumer Service

23andMe launched its U.S. Personal Genome Service on November 16, 2007. Customers provided a saliva sample, and the company used genotyping of selected genetic markers to generate online information about ancestry, inherited traits and, within changing regulatory boundaries, certain health-related risks.

The early product cost $999. In January 2008, 23andMe expanded availability to Canada and several European countries; later that year it reduced the price to $399. TIME named the retail DNA test its 2008 Invention of the Year, bringing wide attention to the young company.

Alongside its personal reports, 23andMe developed a research platform based on voluntary participation. Customers could separately opt in, answer surveys and allow their genetic information to support studies. The distinction between customers and consented research participants became increasingly important as the database grew.

Wojcicki’s formally documented chief-executive tenure began in 2010. By June 2015, the company reported having genotyped more than one million customers.

When the FDA Challenged the Health Reports

The growing service encountered a major regulatory boundary in November 2013. The U.S. Food and Drug Administration warned 23andMe about marketing the health-related portions of its Personal Genome Service without the required authorization. The company acknowledged problems with its communications and regulatory timetable, suspended its U.S. health-related interpretations and continued ancestry services and access to raw data.

Wojcicki later said the company’s leadership had initially regarded established laboratory standards as a sufficient starting point. The FDA’s medical-device requirements, she explained, demanded additional validation and work on whether consumers understood the reports.

A more limited health-testing service returned through specific permissions. In 2015 the FDA authorized a Bloom syndrome carrier-status test. In April 2017 it authorized certain genetic health-risk reports involving selected conditions, including markers associated with late-onset Alzheimer’s and Parkinson’s disease. In March 2018 it authorized a BRCA1/BRCA2 report covering a limited set of variants.

Each authorization covered specific tests and defined genetic variants. For example, the FDA warns that a negative result from a limited-variant BRCA report cannot rule out other risk-associated variants and should not replace medical care. The regulatory process reshaped which health reports 23andMe could offer and how it could present them.

From Research Participation to Drug Discovery

In 2014, 23andMe contributed to a broad scientific collaboration published in Nature Genetics that identified six additional genetic loci associated with Parkinson’s disease.

The company’s research ambitions moved further toward drug discovery on July 25, 2018, when it announced a four-year collaboration with GSK. The partnership aimed to combine voluntarily contributed genetic and health information with pharmaceutical expertise to identify potential disease targets and develop candidate medicines.

Outside 23andMe, Wojcicki was a founding sponsor of the Breakthrough Prize in Life Sciences, launched in 2013 to recognize major scientific achievements.

A Public Listing and a Broader Healthcare Bet

In February 2021, 23andMe announced plans to combine with VG Acquisition Corp., a special-purpose acquisition company associated with Richard Branson. The proposed SPAC deal assigned the business an estimated enterprise value of $3.5 billion. The merger closed on June 16, and 23andMe began trading publicly around June 17.

23andMe next moved into telehealth. On November 1, 2021, it completed its acquisition of Lemonaid Health for announced terms of approximately $400 million, seeking to connect consumer genetics with broader healthcare services.

Under Wojcicki’s leadership, 23andMe now operated across consumer DNA testing, pharmaceutical research partnerships and telehealth. Financial pressures soon became a defining challenge for the wider enterprise.

A Data Breach, Board Conflict and Shrinking Cash

23andMe faced a serious data-security incident in 2023. Between April and September, attackers used credential stuffing to enter more than 18,000 customer accounts. Through connected DNA-relative features, information associated with nearly seven million people worldwide was exposed. The type and amount of information exposed varied across individuals.

Meanwhile, sales of consumer DNA kits were weakening. Many customers had little reason to buy the same kind of test repeatedly, creating a challenge for the company’s business model. The publicly traded company continued to report losses and faced mounting pressure on its finances.

Wojcicki proposed taking 23andMe private for $0.40 per share in July 2024. The board’s special committee rejected the nonbinding offer in August, citing the absence of an adequate price premium, firm financing and sufficient certainty. On September 17, independent directors resigned, saying months of talks had not produced a sufficiently financed, actionable transaction.

In November 2024, 23andMe announced a workforce reduction of roughly 40% and stopped further development of its internal therapeutics programs. By December 31, cash and cash equivalents had fallen to $79.4 million from $216.5 million on March 31. The company warned that it needed additional liquidity.

Bankruptcy, Resignation and the $305 Million Bid

23andMe Holding Co. and certain subsidiaries sought Chapter 11 protection on March 23, 2025. Wojcicki resigned as the original company’s CEO the same day, while initially remaining a director. Explaining her decision to a congressional committee, she wrote: “I resigned so I could pursue an acquisition of the Company as an independent bidder.”

The first selected buyer was Regeneron, with a proposed $256 million purchase of core assets in May 2025. Wojcicki’s affiliated nonprofit, TTAM Research Institute, subsequently offered $305 million. The sale process reopened, and TTAM was selected in June; the bankruptcy court approved the transaction later that month.

On July 14, 2025, TTAM completed the acquisition of the Personal Genome Service and Research Services operations for $305 million. The organization subsequently operated as 23andMe Research Institute. Lemonaid Health was excluded from that completed genetic-testing and research transaction and was addressed separately in the bankruptcy wind-down.

The sale placed the core genetics and research operations under a legally separate nonprofit. Claims and objections involving the original holding company remained part of the bankruptcy’s aftermath.

The Privacy Questions Did Not End with the Sale

Privacy concerns had already become central to the sale process. State authorities and legislators questioned how sensitive genetic information would be handled under new ownership. On June 10, 2025, Wojcicki testified before a U.S. House committee about the bankruptcy and her approach to protecting customer data. She described privacy as part of 23andMe’s original mission.

In June 2025, a joint Canadian and British privacy investigation documented failures in the original company’s prevention, detection and response to the 2023 attack. Among the shortcomings was the absence of mandatory multifactor authentication at the time. The U.K. Information Commissioner’s Office imposed a £2.31 million fine on 23andMe.

California opposed the transfer under its genetic-information privacy law. Both the bankruptcy court and a district court rejected the state’s objections, according to California’s attorney general, while concerns over consent to the transfer remained a focus of scrutiny.

Corporate breach litigation and bankruptcy claims continued through 2026. A U.S. consumer class action concerning the 2023 incident received final settlement approval in January, with the final amount set at $46.75 million on July 7. Separately, 42 state attorneys general reached a bankruptcy-claims resolution recognizing $150 million in allowed claims, with $18 million expected to be distributed from estate funds.

On October 19, 2026, California announced a proposed $6 million settlement with Chrome Holding Co., formerly 23andMe, concerning the data breach and the genetic-data sale dispute. As of October 23, the agreement still awaited bankruptcy-court approval.

Leading a Nonprofit with Millions of Research Participants

As of October 23, 2026, Wojcicki was founder and CEO of 23andMe Research Institute. The organization had appointed a Privacy Advisory Board in October 2025 and announced an inaugural Scientific Advisory Board in October 2026. It presented these bodies as part of its data-stewardship and scientific plans, while the questions raised by the previous company’s security record remained.

In a June 2026 interview, Wojcicki set out a goal of reaching 100 million users to support research on a much larger scale, particularly in an era of AI-enabled scientific work. By October 2026, the institute reported more than 11 million consented research participants; this was its reported research cohort, measured separately from total customers.

A Mission Carried into a Different Organization

The enterprise Wojcicki helped found in 2006 changed ownership and legal form after its bankruptcy, but the ambition to combine consumer access to genetic information with voluntary participation in research continued under her leadership of the nonprofit institute.

That continuity sits alongside difficult questions about safeguarding sensitive data and sustaining a large-scale research model. As of October 2026, the institute’s long-term scientific results, financial durability and success in earning confidence in its stewardship remained to be established.

Timeline

These milestones trace Anne Wojcicki’s education, the development of 23andMe and the later nonprofit transition.

Timeline.

1973

Anne Wojcicki is born.

1996

Graduates from Yale University with a bachelor’s degree in biology and begins an investment-research role at Investor AB.

2006

Co-founds 23andMe with Linda Avey and Paul Cusenza.

November 16, 2007

23andMe launches its Personal Genome Service in the United States.

2008

Service availability expands to Canada and several European countries. TIME names the retail DNA test its Invention of the Year.

2010

Begins the CEO tenure later documented in company SEC filings.

2013

Becomes a founding sponsor of the Breakthrough Prize in Life Sciences. The FDA warns 23andMe about marketing health-related genetic reports.

2015–2017

The FDA authorizes a Bloom syndrome carrier-status test in 2015 and certain genetic health-risk reports in 2017. In 2015, the company says it has genotyped more than one million customers.

2018

The FDA authorizes a limited-variant BRCA report; 23andMe announces a four-year drug-discovery collaboration with GSK.

2021

23andMe closes its SPAC merger and begins public trading in June; it completes the Lemonaid Health acquisition in November.

2023

Attackers directly access more than 18,000 accounts; connected DNA-relative features expose information associated with nearly seven million people worldwide.

2024

A special committee rejects Wojcicki’s take-private proposal; independent directors resign; the company announces major workforce reductions and an exit from its internal therapeutics development programs.

March–July 2025

The original holding company files for Chapter 11; Wojcicki steps down as CEO. After a reopened sale process, her affiliated nonprofit completes the $305 million acquisition of the genetics and research operations on July 14.

October 2025

The nonprofit successor appoints a Privacy Advisory Board.

2026

Wojcicki describes a goal of reaching 100 million users. The institute announces a Scientific Advisory Board and reports more than 11 million consented research participants. The old company’s breach settlements proceed, and a proposed California settlement awaits court approval as of October 23.

FAQs

Did Anne Wojcicki found 23andMe alone?

Anne Wojcicki co-founded 23andMe in 2006 with Linda Avey and Paul Cusenza. All three appear in the company’s fuller founding history.

Why did the FDA restrict 23andMe’s health testing?

In 2013, the FDA objected to the marketing of health-related genetic reports without the required authorization. 23andMe suspended U.S. health interpretations and later obtained permission for specific carrier-status and genetic-health-risk reports.

Can a 23andMe genetic-health report replace a medical diagnosis?

Genetic-health reports test defined markers and provide limited information about specific risks. They cannot replace clinical care; for example, a negative result from a limited-variant BRCA report cannot rule out other disease-associated variants.

Did Anne Wojcicki personally declare bankruptcy in 2025?

23andMe Holding Co. and certain subsidiaries filed for Chapter 11 in March 2025. Wojcicki resigned as the company’s CEO to pursue a separate bid for its assets.

Who acquired 23andMe’s genetics business, and was Lemonaid included?

Wojcicki-founded TTAM Research Institute acquired 23andMe’s consumer genetic-testing and research operations for $305 million on July 14, 2025. The nonprofit, later named 23andMe Research Institute, was legally separate from the bankrupt holding company. The acquisition excluded Lemonaid Health.

Were nearly seven million 23andMe accounts directly hacked?

The 2023 attack directly accessed more than 18,000 customer accounts through credential stuffing. Connected DNA-relative features exposed information associated with nearly seven million people, with the extent of exposure varying by individual.

Had 23andMe Research Institute reached 100 million users by October 2026?

Wojcicki described 100 million users as a future goal in June 2026. In October, the institute reported more than 11 million consented research participants, a separate measure from total users.

Interviews

How 23andMe Began — PLOS Genetics, 2015

In Jane Gitschier’s interview, Wojcicki looks back on her work as a biotechnology research analyst, how she connected with Linda Avey and the early thinking behind consumer-accessible genetic information. She also discusses the FDA’s regulatory position and the company’s response. It is especially valuable as her firsthand account of the career change and startup period.

Read the interview

Consumer Empowerment and Prevention — Stanford Biodesign

Stanford Medicine’s conversation with Wojcicki revisits her move from investment analysis toward genetic testing and research participation. Her comments explain how she framed prevention, access to information and consumer agency in healthcare. It offers a direct perspective on the ideas she associated with 23andMe’s creation.

Read the conversation

Resignation, Bankruptcy and Genetic-Data Privacy — Congressional Testimony, 2025

In written testimony for a June 10, 2025, U.S. House hearing, Wojcicki discusses why she resigned as CEO and sought to bid independently during the bankruptcy sale. She also explains her position on genetic-data protection and 23andMe’s original mission.

Read the testimony

After the Bankruptcy — The Circuit with Emily Chang, 2026

In this June 2026 video interview, Wojcicki discusses the bankruptcy and the nonprofit chapter of the 23andMe story. The conversation is a companion to coverage of her stated ambition to build a far larger research participant base. Readers can hear her describe the institute’s aspirations in her own words.

Watch the interview

Sources